Gastroenterology Market Research, Studies & Insights
Spherix Global Insights’ Gastroenterology therapeutic team is a leading provider of independent syndicated gastroenterology market research, insights & business intelligence.
On an annual basis, Spherix’s Gastroenterology team publishes over 26 studies in seven different indication areas including: Crohn’s Disease, ulcerative colitis, inflammatory bowel, celiac disease, clostridioides difficile, primary biliary cholangitis, eosinophilic esophagitis, non-alcoholic fatty liver disease & non-alcoholic steatohepatitis.
Unparalleled Gastroenterology Therapeutic Expertise
Our team of Gastroenterology experts delivers insights to pharmaceutical, life sciences, and biotechnology companies derived from gastroenterologists, healthcare providers & professionals, key opinion leaders, and the entire life sciences community. Insights from these experts help inform your product development and go-to-market strategies, helping you stay patient-focused at every step of the process.
Spherix Global Insights Gastroenterology – Your Trusted Advisor
Our clients are facing unprecedented challenges globally and must have the scientific, commercial, and operational capabilities necessary to thrive in an increasingly complex health care environment. As a trusted advisor, Spherix’s Gastroenterology syndicated market research studies empower our clients to innovate, thrive, and grow from development to launch.
Follow Spherix Gastroenterology on Social Media
Follow us for gastroenterology industry news, insights & analysis:
Twitter: https://twitter.com/SpherixGastro
LinkedIn: https://www.linkedin.com/company/spherix-global-insights/
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:
More than one million Americans suffer from inflammatory bowel disease (IBD), divided between Crohn’s disease and ulcerative colitis. A distinguished physician-scientist and international leader in the treatment of IBD, Stephen B. Hanauer, MD , and his colleagues have come so far in understanding and treating IBD that their work may become a model for treating other immune-mediated inflammatory disorders, such as rheumatoid arthritis, psoriasis, and lupus. Hanauer joined Feinberg in January 2014 as the Clifford Joseph Barborka Professor of Medicine and the medical director of the Digestive Disease Center. He serves as chair of the International Organization for Inflammatory Bowel Disease, secretary-elect of the American College of Gastroenterology, and is a member of the GI Specialty Board of Internal Medicine, the American College of Physicians, and American Gastroenterology Association. He previously served as chair of the Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee, where he authored the FDA’s “Guidelines for Clinical Evaluation of Drugs for Patients with Inflammatory Bowel Disease.”
Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber...
Spherix Global Insights finds doctors have yet to define where APT-1011 will sit in the treatment path relative to EoE...
As fatty liver disease gets a new name, will it also finally get approved drug treatments? That’s what healthcare professionals...
Spherix Global Insights finds gastroenterologist and hepatologist capacity is being stretched to the limit by increasing demand from MASLD/MASH patients...
